What is Psyomics?
Founded in 2015 by Professor Sabine Bahn of the University of Cambridge and CEO Dan Cowell, Psyomics operates at the intersection of neuroscience and digital health. The company is dedicated to addressing the systemic inefficiencies in mental health care by improving the speed and accuracy of diagnostic identification. Through its innovative platform, Psyomics provides clinicians with data-driven insights that facilitate more precise patient pathways, effectively bridging the gap between complex biological research and practical clinical application. As a high-growth HealthTech entity, the firm is positioned to disrupt traditional diagnostic models by introducing objective, evidence-based methodologies into psychiatric practice.
How much funding has Psyomics raised?
Psyomics has raised a total of $10M across 3 funding rounds:
Unspecified
$2M
Unspecified
$2.9M
Other Financing Round
$5.1M
Unspecified (2020): $2M with participation from Parkwalk Advisors Limited, Jonathan Milner, Cambridge Enterprise, and Martlet
Unspecified (2022): $2.9M led by Parkwalk
Other Financing Round (2024): $5.1M supported by Parkwalk Advisors
Key Investors in Psyomics
Parkwalk Advisors
Parkwalk is a leading investor in university spinouts, focusing on deeptech innovations emerging from the UK's top universities. They bridge the gap between academic research and commercial success by providing funding and expertise to help companies thrive.
Cambridge Enterprise
The commercialization arm of the University of Cambridge, dedicated to helping students and staff translate their research and expertise into commercial ventures that benefit society.
Martlet
An early-stage investment firm focused on supporting high-potential technology companies, providing the necessary capital and strategic guidance to foster long-term growth.
What's next for Psyomics?
With the recent infusion of capital, Psyomics is well-positioned to transition into a phase of rapid commercial scaling and product refinement. The strategic focus will likely center on expanding the clinical utility of its diagnostic tools and strengthening its presence in international healthcare markets. By leveraging its deep-rooted academic partnerships and the expertise of its investor base, the company aims to solidify its role as a standard-bearer for objective mental health diagnostics. Future growth will be defined by the successful integration of its technology into broader healthcare systems, ultimately aiming to reduce the diagnostic burden on clinicians and improve patient outcomes on a global scale.
See full Psyomics company page
